Zentalis reports 15.8-month median overall survival with azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer

Bitget2026/10/18 22:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zentalis Pharmaceuticals announced its first overall survival results for azenosertib from DENALI Part 1b, published in an ESMO Congress 2026 abstract.
Survival was longer in Cyclin E1-positive platinum-resistant ovarian cancer patients than in the biomarker-negative subgroup, with no new safety signals observed.
The abstract reported favorable survival compared with historical single-agent chemotherapy benchmarks in the biomarker-positive group, not a direct trial comparison.
Results support further development in biomarker-selected patients through ongoing DENALI Part 2 and ASPENOVA Phase 3 confirmatory trials.
The data will be presented at ESMO Congress in Madrid on October 23, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610181805PRIMZONEFULLFEED9847969) on October 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zentalis reports 15.8-month median overall survival with azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer

You may also like

Crypto prices